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Natural killer group 2D (NKG2D) is a natural killer (NK) cell-activating receptor that
recognizes different stress-induced ligands that are overexpressed in a variety of
childhood and adult tumors. NKG2D chimeric antigen receptor (CAR) T cells have
shown potent anticancer effects against different cancer types. A second-generation
NKG2D CAR was generated by fusing full-length human NKG2D to 4-1BB costimulatory
molecule and CD3ζ signaling domain. Patient-derived CAR T cells show limitations
including inability to manufacture CAR T cells from the patients’ own T cells, disease
progression, and death prior to return of engineered cells. The use of allogeneic T cells
for CAR therapy could be an attractive alternative, although undesirable graft vs. host
reactions may occur. To avoid such adverse effects, we used CD45RA− memory T
cells, a T-cell subset with less alloreactivity, as effector cells to express NKG2D CAR.
In this study, we developed a protocol to obtain large-scale NKG2D CAR memory T
cells for clinical use by using CliniMACS Prodigy, an automated closed system compliant
with Good Manufacturing Practice (GMP) guidelines. CD45RA+ fraction was depleted
from healthy donors’ non-mobilized apheresis using CliniMACS CD45RA Reagent and
CliniMACS Plus device. A total of 108 CD45RA− cells were cultured in TexMACS media
supplemented with 100 IU/mL IL-2 and activated at day 0 with T Cell TransAct. Then,
we used NKG2D-CD8TM-4-1BB-CD3ζ lentiviral vector for cell transduction (MOI = 2).
NKG2D CAR T cells expanded between 10 and 13 days. Final cell products were
analyzed to comply with the specifications derived from the quality and complementary
controls carried out in accordance with the instructions of the Spanish Regulatory
Agency of Medicines andMedical Devices (AEMPS) for the manufacture of investigational
advanced therapy medicinal products (ATMPs). We performed four validations. The
manufacturing protocol here described achieved large numbers of viable NKG2D CAR
memory T cells with elevated levels of NKG2D CAR expression and highly cytotoxic
against Jurkat and 531MII tumor target cells. CAR T cell final products met release
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criteria, except for one showing myc overexpression and another with viral copy number
higher than five. Manufacturing of clinical-grade NKG2D CAR memory T cells using
CliniMACS Prodigy is feasible and reproducible, widening clinical application of CAR
T cell therapies.
Keywords: NKG2D CAR, memory T cells, automated production, large-scale, clinical-grade, CliniMACS prodigy
INTRODUCTION
Redirected chimeric antigen receptor (CAR) T cells (CART)
have shown effective potency against hematologic tumors (1, 2).
Second-generation CARs are hybrid receptors comprising a
recognition domain, normally derived from a single-chain
antibody fragment (scFv), fused to costimulatory, and cytotoxic
signaling domains that enhance T cell function (3, 4). This
restricts CAR T cells to recognize a single tumor antigen in
a defined set of tumors, such as CD19 in B-cell malignancies.
CD19-specific CAR T cell therapy for the treatment of CD19-
positive B cell malignancies such as B-cell acute lymphoblastic
leukemia (B-ALL), B-cell non-Hodgkin lymphoma (NHL),
or chronic lymphocytic leukemia (CLL) has had remarkable
success (5–8), resulting in their recent US Food and Drug
Administration (FDA) approval. However, relapse of leukemia
through CD19 loss variants in leukemia/lymphoma patients
and immunosuppressive microenvironment or lack of tumor-
associated antigens (TAAs) in solid tumors (9–11) represents
major challenges for CAR T cell therapies. These inconveniences
along with antigen-loss escape make it necessary to focus in other
possible TAAs (9).
Natural killer group 2D (NKG2D) is an activating receptor
expressed on different immune effector cells [natural killer
(NK), CD8, and γδ T cells], although is in the NK cells
where it has a main role in tumor surveillance. Ligands for
NKG2D receptor, namely, MIC-A, MIC-B, and the UL-16
binding proteins, are expressed in 70% of human cancers
including leukemia, osteosarcoma, or Ewing sarcoma (11–13),
whereas their expression in healthy tissues is rare. We have
produced a second-generation NKG2D CAR by fusing the full-
length extracellular domain of human NKG2D to 4-1BB, which
provides a costimulatory signal, and CD3ζ signaling domain.
Thus, through the expression of this CAR, T cells acquire NK
cell anti-tumor specificity while maintaining T-cell ability to
expand and persist in vivo. The main advantages of this CAR
are (1) the recognition of different ligands, widening clinical
application, and potentially avoiding tumor immune escape by
single antigen loss, and (2) it is a fully human CAR, causing
less immunogenicity.
Most clinical trials use autologous T cells to express CARs;
however, owing to low T-cell numbers, poor quality, or rapid
disease progression, manufacturing of patient-derived CAR T
cells is not always possible. To overcome these limitations, we
propose here the use of allogeneic CAR T cells. Allogeneic
cells expressing CARs have been infused into patients after a
hematopoietic stem cell transplantation (HSCT) from the same
healthy donor (14, 15). Nevertheless, the universal availability
of large numbers of healthy donor T cells to express CARs
and their infusion into patients without the requirement of
a prior HSCT would be major challenges of CAR T cell
immunotherapy. One potential risk of the use of allogeneic
T cell-based therapies is the T-cell response against normal
tissue: graft-vs.-host disease (GvHD). To avoid undesirable
GvH reactions, T-cell products lacking an alloreactive T-cell
receptor (TCR) are needed. Several methods have attempted
to intensify graft-vs.-tumor (GvT) effects while minimizing
GvH responses to lower toxicity and improve the outcome of
treatment (14, 16, 17). One approach to enrich non-allogeneic T
cells is by using antigen-experienced memory T cells for CAR
transduction (16, 18). Predictably, the vast majority of T cells
with amemory phenotype are likely to have encountered antigens
other than the allogeneic type. Thus, selection for memory
phenotype cells should enrich for a non-alloreactive repertoire.
Indeed, memory T cells showed less potential to generate GvHD
in murine models (19, 20), in part owing to non-alloreactive
TCR enrichment along with the evidence that memory T
cells are less likely to traffic to GvHD organs such as the
gastrointestinal tract. Different extracellular markers can be used
to differentiate naïve from memory T cells. Commonly, naïve T
cells are CD45RA+CD45RO−CCR7+CD62L+, central memory
T cells (TCM) are CD45RA
−CD45RO+CCR7+CD62L+, effector
memory T cells (TEM) are CD45RA
−CD45RO+CCR7−CD62L−,
and effector cells are CD45RA+CD45RO−CCR7−CD62L− (21).
Thus, one marker to roughly distinguish naïve from memory T
cells is CD45RA (22). CD45RA is expressed on naïve T cells and
a minor population of T memory stem cells (TSCM) (21), whereas
CD45RO is expressed on memory T cells (22). CD45RA+
naïve T cells have high potential for alloreactivity against
recipient-specific antigens upon adoptive transfer, causing
clinical GvHD (23, 24). In contrast, CD45RA−CD45RO+
T cells exert a memory response to prior pathogens or
vaccines and can mediate GvT effects without inducing
GvHD (19, 25).
In the present study, we describe the manufacturing process
to produce large-scale NKG2D CAR memory T cells from
healthy donors for clinical use. In CAR T cell therapies, besides
the designing of genetic constructs, the choice of effector cells
to transduce, and the clinical trial design, the methods used
to produce CAR T cells are key for clinical success. Thus,
detailed description of each step along themanufacturing process
and the full analysis of CAR T cell products composition at
every step are essential. In fact, and according to the Good
Manufacturing Practice (GMP) manufacturing standard, during
the manufacturing procedure, in-process controls are carried out
at different times. Optimization of manufacturing protocols to
improve reproducibility, cost-effectiveness, and scalability will
enable a broad application of CAR T cell therapies.
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The NKG2D CAR memory T cells showed in this study were
manufactured after 10–13 days of ex vivo processing, described
in detail below, including activation with TransAct and IL-2,
transduction with an NKG2D-CD8TM-4-1BB-CD3ζ lentiviral
vector at multiplicity of infection (MOI) = 2, and expansion
in CliniMACS Prodigy device. The NKG2D CAR memory T
cells collected after this process fulfilled the release criteria
with respect to safety, purity, and potency established in the
protocols adhered to the guidelines of the current GMP (26–28).
The manufacturing process developed in this study allows the
automated GMP-compliant production of large doses of clinical-
grade NKG2D CAR T cells in a short time and provides a
robust and flexible base for further optimization of NKG2D CAR
T cells manufacturing for their clinical application in different
tumor types.
MATERIALS AND METHODS
Starting Material
Non-mobilized apheresis was obtained from healthy donors at
the BoneMarrow Transplant and Cell Therapy Unit (BMTCT) of
Hospital Universitario La Paz (HULP) by using CliniMACS Plus
device (Miltenyi Biotec). All donors gave their written informed
consent in accordance with the Declaration of Helsinki protocol,
and the study was performed according to the guidelines of the
local ethics committee. All donors comply with the requirements
regarding quality and safety for donation, obtaining, storage,
distribution, and preservation of human cells and tissues under
the Spanish specific regulation. CD45RA+ cells were depleted
by immunomagnetic separation using CliniMACS CD45RA
Reagent (701-46) and CliniMACS Plus system, both from
Miltenyi Biotec, following manufacturer instructions. CD45RA−
cells were either processed immediately or stored at 2–8◦C for
subsequent processing no later than 24 h after depletion. The
viability and purity of CD45RA− fraction were analyzed by flow
cytometry (FCM) before activation, transduction, and expansion.
Construction and Production of Lentiviral
Vector
The HL20i4r-MNDantiCD19bbz lentiviral vectors were derived
from the clinical vector CL20i4r-EF1a-hgcOPT27 but expressed
an NKG2D CAR. The anti-CD19-4-1BB-CD3ζ CAR designed
by Imai et al. (29) was used as backbone to build the NKG2D
CAR construct. It contained the extracellular domain of NKG2D
(designed by Wai-Hang Leung and Wing Leung), the hinge
region of CD8a, and the signaling domains of 4-1BB and CD3ζ.
The cassette was driven by a prMND. The viral supernatant was
produced according to GMP guidelines by transient transfection
of HEK293T cells with the vector genome plasmid and lentiviral
packaging helper plasmids pCAGG-HIVgpco, pCAGG-VSVG,
and pCAG4-RTR2. Lentiviral plasmids were kindly provided by
Dr. Byoung (St. Jude Children’s Research Hospital). The virus
supernatants were harvested and filtered through 0.22µm filters.
Virus supernatant was concentrated by ultracentrifugation and
titrated on HeLa cells by serial dilution followed by a quantitative
polymerase chain reaction (qPCR) to determine vector genome
copy number.
Manufacturing of Clinical-Grade NKG2D
CAR T Cells
Activation, transduction, and expansion of CD45RA− cells were
performed on the CliniMACS Prodigy using Tubing set TS520
(170-076-600) and T-cell transduction (TCT) process. In detail,
at day 0, cultivation was initiated with 108 CD45RA− cells in a
total volume of 70mL of TexMACs GMPmedium (170-076-306)
+ 100 IU/mL of MACS GMP human recombinant IL-2 (170-
076-147). MACS GMP TransAct CD3/CD28 Kit (170-076-156)
was used for a 24-h activation at a final dilution of 1:17.5, as
recommended by the manufacturer. At the following day, cells
were transduced with NKG2D-4-1BB-CD3ζ lentiviral particles at
MOI = 2. The vector was diluted in 10mL of medium in a 150-
mL transfer bag, which was attached to the CliniMACS Prodigy
by sterile welding. The vector was automatically transferred in
the culture chamber, and the vector bag was further rinsed with
20mL of medium to bring the total culture volume to 100mL.
Residual TransAct was removed by an automated culture wash
on day 4. Cells were then expanded for 10–13 days before being
harvested. Sampling was performed at days +6 and +8 for in-
process controls including cell counts, cytotoxicity, and FCM. At
the end of the expansion, cells were automatically collected in
0.9% sodium chloride solution supplemented with 0.5% human
serum albumin (Albutein 20%, Grifols) and transferred into a
sterile bag. Release quality controls were performed at the end
of the process.
Analysis of Viability and Surface
Immunophenotype by FCM
At day +6 and between days +8 and +10, as in-process
controls, and at harvest, as release controls, NKG2D CAR
memory T cell products were counted in a CELL-DYN Emerald
hematology analyzer (Abbott) and analyzed for their viability,
immunophenotype, NKG2D CAR expression, and activation
status by FCM. The following anti-human fluorochrome-labeled
monoclonal antibodies (mAb) were purchased from BioLegend:
CD45RA-APC (Clone H100, 304111), CD3-PE/Cy7 (Clone
HIT3a, 300316), CD4-APC/Cy7 (Clone OKT4, 317417), CD8
FITC (Clone KK1, 344703), NKG2D-PE (Clone 1D11, 320806),
CD4 PerCP (Clone OKT4, 31743125), PD-1 APC (Clone
EH12.2H7, 329907), Tim-3 APC Cy7 (Clone F38-2E2, 345025),
CD25 APC (Clone BC96, 302610), and CD127 PE/Cy7 (Clone
A019D5, 351320). Anti-human CD45RO-APC-Vio770 (Clone
REA611, 130-114-083) was purchased from Miltenyi Biotec.
Anti-human CCR7 PE (Clone 3D12, 552176) was purchased
from BD Biosciences. The viability was tested by using DAPI
or 7AAD as dead cell exclusion markers. Cells were analyzed
using FACS CANTO II (BD Biosciences) and FlowJo v10.5.3
software (TreeStar). To ensure the expression of NKG2D CAR in
the manufactured NKG2D CAR T cell products, we performed
western blot with an antibody detecting CD3ζ. Total peripheral
blood mononuclear cells (PBMC), activated and expanded NK
cells (NKAE), untransduced CD45RA−, and NKG2D CAR T
cells were pelleted and frozen at −80◦C. Cell lysates were
obtained by incubating cell pellets with RIPA (Millipore,
20188) supplemented with phosphatase inhibitor (PhosSTOP,
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04906845001) and a cocktail of protease inhibitors (cOmplete
Mini, 11836153001), both from Roche. Proteins were quantified
using Bradford reagent (Bio-Rad Laboratories, 500-0205) and
measuring absorbance at 595 nm in a Victor Plate Reader. Cell
lysates were then mixed with the Laemmli sample buffer (Bio-
Rad Laboratories, 161-0747), and equal amounts of protein (20
µg) were loaded on 4–15%Mini-PROTEAN TGX Gels (Bio-Rad
Laboratories, 456-1086). Gels were transferred to polyvinylidene
difluoride (PVDF) membranes. Blots were incubated with the
mouse anti-human CD3ζ (BD Biosciences, 551033) or rabbit
anti-human β-actin (Cell Signaling Technology, 4967S) primary
antibodies at 4◦C overnight. Horseradish peroxidase (HRP)-
conjugated anti-mouse (Agilent, P0447) and anti-rabbit (Agilent,
P0448) were used as secondary antibodies. The membranes
were developed by enhanced chemiluminescence and exposed on
ClarityWestern ECL substrate (Bio-Rad Laboratories, 170-5060).
The immunoblotting images were analyzed using the Image
Lab software.
Effector Function
The mechanism of action of CAR cells is complex, and there
are no standardized methods to determine the degree of
action. Although methods are available to determine potency,
comparison of results is not easy owing to the absence of
standardization (26). In our study, to test the cytotoxicity
of manufactured NKG2D CAR T cells, conventional 4-h
europium-TDA assays (PerkinElmer, AD0116) were performed
as previously described (30) using a 20:1 effector to target ratio.
The NKG2DL-expressing cell lines Jurkat and 531MII were
used as targets. Cytotoxicity assays were performed on days +6
and +8 and at the end of the process. The 531MII primary
osteosarcoma cell line was kindly provided by Dr. Patiño-García
(Centro de Investigación Médica Aplicada (CIMA), Universidad
de Navarra, Spain) and was cultured in minimum essential
medium (MEM; GIBCO, 22571-020) supplemented with 10%
heat-inactivated fetal bovine serum (FBS; GIBCO, 10270-098)
and penicillin–streptomycin (P/S; GIBCO, 15140-122). The T-
ALL Jurkat cell line was acquired from American Type Culture
Collection (ATCC) and kept in culture in Roswell Park Memorial
Institute (GIBCO, 61870-010) and 10% FBS and P/S. Both cell
lines were routinely tested for mycoplasma.
Analyses of Non-cellular Impurities
The detection of non-cellular impurities was carried out
in accordance with the methodology recommendations of
Chapter 2.6.21 and 2.6.7 of the European Pharmacopeia (Eu
Ph) for mycoplasma and Chapter 2.6.14 for endotoxins. A
DNA-binding dye-based qPCR system was employed for the
detection of mycoplasma DNA in cell cultures. The assay
was developed by the Genomics Unit in collaboration with
the Monoclonal Antibodies Unit, both from CNIO, to detect
16s rRNA gene sequences from up to 70 Mollicutes species.
Both specificity and sensitivity were extensively tested through
benchmarking with established commercial systems (MTC-NI
System, Millipore/GEN-PROBE Cat. No. 4573 and MycoAlertTM
PLUSMycoplasma Detection Kit, Lonza Cat. No. LT07-705). The
Clinical Microbiology and Parasitology Service of HULP carried
out the endotoxin test Endosafe-PTS (Charles River) to quantify
endotoxin levels at day+8 and in final products.
Microbiological Tests
At days +6 and between days +8 and +10 as in-process
controls and at the end of manufacturing protocol, NKG2D
CAR memory T cell products were tested for sterility according
to Eu Ph 2.6.1. The microbiological tests were developed by
the Clinical Microbiology and Parasitology Service of HULP by
conventional microbiology techniques. In summary, sample tests
were inoculated into separate culture media, and the growth
of viable microorganisms was tested after several days. When
a rapid result was required, Gram staining was used as a non-
culture method, although it is a less sensitive technique than
techniques based on culture (26).
Genetic Tests, Genome Integrated Vector
Copy Number, and Determination of
Replication Competent Lentivirus in the
Supernatant
Genetic tests and determination of vector copy number (VCN)
and replication competent lentivirus (RCL) in the supernatant
were carried out at days +6 and between days +8 and
+10 as quality controls during process validation and at the
end of the manufacturing process between days 10 and 13.
To rule out chromosomal aberrations caused by lentiviral
transduction, comparative genome hybridization (CGH) analysis
was performed as previously described (30). Genome integrated
lentiviral copy number and viral particles in supernatant were
measured by qPCR according to Christodoulou et al. (31)
using TaqMan Universal PCR Master Mix (Thermo Fisher;
4304437) and LightCycler 480 (Roche) after viral RNA extraction
with RNeasy (Qiagen, 74104) and cDNA retrotranscription
with Superscript II (Thermo Fisher, 18064014). The lack of
oncogenic effects of the NKG2D CAR T cell products was
verified using reverse transcriptase (RT)-PCR to detect c-MYC
and telomerase (TERT) expression. Total RNA was isolated from
the PBMCs using the RNeasy kit from Qiagen (PN 74104),
followed by reverse transcription using SuperScriptTM IV First-
Strand Synthesis System from Thermo Fisher (PN 18091050).
The resulting cDNA was amplified with the following specific
TaqMan probes: Hs00972650_m1 (TERT), Hs00153408_m1
(MYC), and Hs02800695_m1 (HPRT1, housekeeping) from
Life Technologies and the LightCycler 480 System from
Roche. Finally, the data were analyzed by the comparative Ct
methods as previously described (32). The genetic tests were
performed at the Institute of Medical and Molecular Genetics of
HULP (INGEMM).
Effects of Cryopreservation on NKG2D
CAR T Cells
As infusion of freshly manufactured CAR T cells is not always
possible, we wanted to determine if cryopreservation could have
a negative impact on viability, NKG2D CAR expression, and
cytotoxicity of NKG2D CAR T cells. To this aim, spare CAR
T cells were frozen at a concentration of 2.5–3 × 105 cells/µL
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either by using HypoThermosol, M199 media supplemented
with 10% human serum albumin and 5% dimethyl sulfoxide
(DMSO), or in autologous plasma supplemented with 5%DMSO.
One year after cryopreservation, NKG2D CAR T cells were
thawed and evaluated for viability, NKG2D expression, and
CD45RA− purity by FCM and for cytotoxicity by europium-
TDA as described above.
Statistics Analyses
All statistical analyses in this study were performed using
GraphPad Prism. Except indicated in another way, results are
shown as median and interquartile range.
RESULTS
Manufacturing Process: Activation,
Transduction, and Expansion
CD45RA− cells from four different donors were activated,
transduced, and expanded in CliniMACS Prodigy in four
different experiments. In-process tests were carried out at days
+6 and +8. At the end of culture (between days +10 and
+13), cells were harvested, and quality/release assays performed.
A schema of the different steps for NKG2D CAR T cells
manufacturing and the quality tests conducted along the process
is shown in Figure 1.
Purity of CD45RA− Starting Cells
Non-mobilized apheresis from four different healthy donors
were obtained and depleted for CD45RA+ cells at CliniMACS
Plus. After depletion of CD45RA+ cells, median of purity of
CD45RA− population was 99.8 (range 99.7–99.9), and median
of viability was 97.9 (range 97.7–99.9). Data of CD45RA− purity
and viability from each experiment are shown in Table 1.
Transduction Efficiency
We transduced CD45RA− cells 1 day after cell activation.
A lentiviral construct encoding for NKG2D CAR was used
at MOI = 2. As CD45RA− cells only have basal levels of
NKG2D receptor expression, we considered that the expression
of NKG2D observed by FCM in NKG2D CAR T cell products
corresponds to NKG2D CAR. Our target goal was to achieve
≥50% transduction of total cells. This goal was achieved for all
four final products. Data from NKG2D CAR expression along
the process are shown in Table 2. Representative dot plots of
NKG2D staining at the different times are shown in Figure 2A.
The anti-NKG2D antibody that we use for FCM does not
discriminate between the NKG2D endogenous receptor and the
NKG2D CAR. In order to analyze the expression of NKG2D
CAR in the transduced cells, we performed a western blot using
an anti-CD3ζ antibody to detect the CAR protein. NKG2D
CAR protein is 40 kDa, whereas endogenous CD3ζ is 16 kDa.
As shown in Figure 2B, bands corresponding to the NKG2D
CAR were only observed in those cell lysates from transduced
CD45RA− cells, whereas they were absent in the different
negative controls (activated and expanded NK cells, PBMC, and
CD45RA− untransduced cells). Additionally, PCR analysis using
specific primers for endogenous NKG2D and NKG2D CAR
genes further confirmed these results (Supplementary Figure 1).
TABLE 1 | Purity and viability of CD45RA− starting cells.
Validation % Viability % of CD45RA−
#1 98.1 99.8
#2 99.9 99.9
#3 97.7 99.9
#4 97.7 99.7
FIGURE 1 | Schema of NKG2D CAR memory T-cell manufacturing process. NKG2D, Natural Killer Group 2D; CAR, chimeric antigen receptor. The schema of
CliniMACS Prodigy is Copyrighted © 2015 by Miltenyi Biotec GmbH, used with permission.
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Expansion
After CD45RA+ depletion, 108 of CD45RA− cells were
transferred into a sterile bag and connected to CliniMACS
Prodigy for further processing. The number of cells recovered
after CD45RA depletion exceeded this limit for all experiments.
For the final products, the fold expansion ranged from 13.4
to 38.6; thus, in all cases, the total number of cells obtained
was enough to perform a clinical treatment in a multiple-dose
regimen. Data of cell expansion from each experiment are shown
in Figure 3.
TABLE 2 | Data from transduction efficiency and viability.
% NKG2D CAR expression Viability
Validation Day +6 Day +8 Final Day +6 Day +8 Final
#1 73 60.5 60.6 85 82.5 86.3
#2 41 43 55 73 77 65
#3 24 82 87.4 70 83 81.4
#4 62 75 91 80 84 82
NKG2D, natural killer group 2D; CAR, chimeric antigen receptor.
Immunophenotype
Starting and final CAR T cell products were analyzed for
viability and CD3, CD4, and CD8 contents. Naïve and memory
populations were also identified by using CD45RA and CCR7
markers. The activation/exhaustion status of starting and
final cells was analyzed by CD25, PD-1, and TIM-3 markers.
The presence of CD4+CD25+CD127low/neg (Tregs) was also
analyzed in the starting and final products. Both starting
FIGURE 3 | Fold expansion of cells along the time in each manufacturing
validation.
FIGURE 2 | NKG2D CAR expression in CD45RA− cells after transduction. (A) Representative FCM data showing an increase in NKG2D CAR expression along the
manufacturing process. (B) Analysis of NKG2D CAR expression in transduced cells by western blot detecting CD3ζ. NKG2D, natural killer group 2D; CAR, chimeric
antigen receptor; FCM, flow cytometry.
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CD45RA− cells and final NKG2D CAR memory T cell products
were CD3+ and showed an enrichment in CD4+ vs. CD8+
T cells. Before and after manufacturing process, T cells were
negative for CD45RA and CCR7, indicating an effector memory
(TEM) phenotype. Tim-3 and CD25 activation/exhaustion
markers were upregulated in final NKG2D CAR memory T
cell products compared to starting CD45RA− cells; however,
PD-1 expression was downregulated at the end of the process
(Figure 4). Additionally, only a low proportion of Tregs
(CD4+CD25+CD127low/neg) was found on starting CD45RA−
cells and final NKG2D CAR T cells compared with total
PBMC (Supplementary Figure 2).
Effector Function
Lysis ability of NKG2D CAR T cells was tested against the
NKG2DL-expressing cell lines Jurkat (T-ALL) and 531MII
(metastatic osteosarcoma) by performing conventional 4-h
europium-TDA assays. Although donor variability was observed,
all final NKG2DCART cell products analyzed could target Jurkat
and 531MII cells with a percentage of cytotoxicity ≥20%, thus
meeting the established requirements. For validation #1, owing
to technical issues, cytotoxicity against Jurkat cells was only
tested using cryopreserved NKG2D CAR T cells. Cytotoxicity
of final NKG2D CAR T cells against Jurkat was higher (median
80%, range 28.2–100%) than against 531MII cells (median
42.3%, range 20–74.6%) for all analyzed products, although this
difference was not statistically significant. Data of cytotoxicity
levels from each experiment are shown in Table 3. Additionally,
the cytotoxicity of manufactured NKG2D CAR T cells against
Jurkat cells is shown in Supplementary Video 1.
Safety and Purity Tests
To meet regulatory specifications (acceptable thresholds in
parentheses), samples were taken at days +6 and between days
TABLE 3 | Cytotoxicity of NKG2D CAR memory T cells against Jurkat and 531MII
target cells.
Validation % Cytotoxicity vs. Jurkat % Cytotoxicity vs. 531MII
#1 NR 74.6
#2 100 19.5
#3 79.8 42.3
#4 28.2 NR
NKG2D, natural killer group 2D; CAR, chimeric antigen receptor; NR, non-reproducible
experiment.
FIGURE 4 | Representative FCM data of starting CD45RA− cells (day 0) and NKG2D CAR memory T cell products at the end of manufacture process (day +12). (A)
CD3, CD4, and CD8 contents. (B) Naïve/memory phenotype. (C) Expression of activation/exhaustion markers. FCM, flow cytometry; NKG2D, natural killer group 2D;
CAR, chimeric antigen receptor.
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+8 and +10 as in-process controls and at the end of process as
release controls and were evaluated for VCN (≤5 copies/cell),
free lentiviral particles in the supernatant (LVPS) (≤0.05%),
oncogenic gene expression (no overexpression), and genetic
stability (normal CGH). A Gram stain (no organisms seen) as
a quick method and microbiological tests [0 colony-forming
unit (CFU)] ensured no bacterial contamination. Other release
controls performed included those relating to the purity of the
final product: measurement of endotoxin levels, whose limits
for administration depend on the product and the parenteral
administration route, where the pyrogenic threshold dose of
endotoxin per kilogram of body mass in a single hour in
the case of transduced cells is 5 IU/kg/h. All final products
analyzed fulfilled the specifications except for validation #3,
which showed VCN of 12 instead of ≤5 copies/cell, and for
validation 4#, which showed overexpression of myc. Complete
data regarding genetic tests are shown in Table 4. All samples
showed no microbiological contamination. Endotoxin levels
were below 5 IU/kg/h, and the presence of mycoplasma was
undetectable (Table 5).
Stability of Cryopreserved NKG2D CAR T
Cells
CliniMACS Prodigy allows the production of sufficient number
of CAR T cells to be administered in multiple doses. Although
the first dose could be administered right after harvesting,
spare cells need to be cryopreserved for future infusions. To
explore if cryopreservation could have a negative impact on
manufactured CAR T cells, we tested three different freezing
media and evaluated cell counts, viability CD45RA− purity,
NKG2D expression, and cytotoxicity of cryopreserved NKG2D
CAR T cells 1 year after freezing. We observed that those
NKG2D CAR T cells cryopreserved in autologous plasma +5%
DMSO showed the highest viability and cytotoxicity indicating
that, whenever possible, this should be the freezing media
TABLE 4 | Results from genetic tests.
Validation VCN LVPS CGH tert expression myc expression
#1 NA Undetectable Normal No overexpression No overexpression
#2 3.6 Undetectable Normal No overexpression No overexpression
#3 12.3 Undetectable Normal No overexpression No overexpression
#4 2.4 Undetectable Normal No overexpression myc overexpression
VCN, vector copy number; LVPS, free lentiviral particles in the supernatant; CGH,
comparative genome hybridization.
TABLE 5 | Results from sterility tests.
Validation Gram staining Mycoplasma Endotoxins EU/mL
#1 Negative Negative NA
#2 Negative Negative 0.019
#3 Negative Negative 0.0035
#4 Negative Negative 0.01
of preference, followed by M199 + 10% albumin and 5%
DMSO (Table 6).
DISCUSSION
In the last decades, CAR T cell-based immunotherapies have
demonstrated to be an effective and safe approach for cancer
treatment. The clinical success of two CART19 cell products
(KymriahTM and YescartaTM) for the treatment of B cell
malignancies has led to their recent FDA and European
Medicines Agency (EMA) approval, emphasizing the great
potential of this technology. Targeting myeloid and non-
B lymphoid cell hematological malignancies such as T-ALL,
biphenotypic, and infant leukemia or solid tumors has been
much harder, owing to the lack of specific antigens and
the immunosuppressive tumor microenvironment (33–36). We
present data on NKG2D CAR, which has the ability to recognize
multiple ligands that are overexpressed in different tumor
types including AML, T-ALL, and sarcomas (12, 13, 37–39).
In fact, D. Sallman et al. have recently reported a case of
remission in a patient suffering from relapsed/refractory AML
after multiple infusions of autologous T cells redirected with
a first-generation CAR recognizing NKG2DL (40). Aside from
CAR specificity, choice of signaling domains and selection of
effector cell subset to transduce, manufacturing process, and
full characterization of final CAR T cell products are essential
for clinical success. In the present study, we validate and
provide detailed description of our manufacturing protocol
and the characteristics of NKG2D CAR T cells. We show the
feasibility of producing large numbers of allogeneic NKG2DCAR
memory T cells using a 10–13 days’ protocol, which includes
activation with TransAct reagent, transduction with an NKG2D-
4-1BB-CD3ζ lentiviral vector and expansion with rhIL-2 in
CliniMACS Prodigy, an automated closed system compliant with
GMP guidelines.
The main objectives of this study were (1) to show the
feasibility and reproducibility of automated manufacturing of
GMP-grade NKG2D CAR T cells in an academic institution and
(2) to demonstrate that manufactured NKG2D CAR T cells meet
the requirements established by the Spanish Regulatory Agency
for clinical use. A total of four manufacturing processes were
completed, and the CAR T cell products obtained were analyzed
TABLE 6 | Stability of manufactured NKG2D CAR memory T cells after
cryopreservation.
Freezing
medium
% Viability % NKG2D % CD45RA− % Cytotox
vs. Jurkat
% Cytotox
vs. 531MII
M199 + ALB
+ DMSO V4
47.9 61.5 99.2 55.2 17.3
Hypothermosol
v4
14.1 61.5 99.2 NA NA
Auto plasma
+ DMSO V5
74.6 69.9 97.1 78.6 60.3
NKG2D, natural killer group 2D; ALB, albumin; DMSO, dimethyl sulfoxide.
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at three different time points: day +6 and between days +8 and
+10, as in-process controls, and at the end of culture, between
days 10 and 13, when quality tests were performed to analyze if
NKG2D CAR memory T cell products met release criteria.
We used CD45RA− cells from healthy donors to produce
our NKG2D CAR T cells in order to develop a safe allogeneic
therapy. The lack of alloreactivity of CD45RA− cells has been
explored before in preclinical studies from our group and others
(18, 30). Furthermore, Maschan et al. have described the safety
of low-dose infusions of CD45RA− lymphocytes in mismatched-
related HSCT (41). Recently, our group has reported the safety
of high-dose infusions of donor-derived CD45RA−CD45RO+ T
cells after haploidentical transplantation (42).
The manufacturing process starts with a non-mobilized
apheresis from a healthy donor followed by depletion of
CD45RA+ cells in CliniMACS Plus device. Although CD45RA+
cells can be currently depleted at CliniMACS Prodigy, at the
moment when these experiments were carried out, the software
to do so was unavailable. After depletion, CD45RA− cells were
tested for viability and purity. All CD45RA− cell products
showed viability >95%. Purity of CD45RA− cells after depletion
of CD45RA+ subset was at least 99.7%, indicating that carryover
of naïve T cells was minimal and meets the established criteria
for further processing to obtain NKG2D CAR T cells. Activation,
transduction, and expansion were conducted in CliniMACS
Prodigy. Median of fold expansion was 24.4 (range 13.5–38.6),
and the mean of total cells obtained was 2.44 × 109 (range 1.35
× 109-3.86 × 109). These expansion data are in line with other
manufacturing protocols using CliniMACS Prodigy (43, 44).
Additionally, according to the number of CAR T cells that have
been infused in other clinical trials (45, 46), the number of
NKG2D CAR T cells we achieved would have been enough to
treat patients in a multiple-dose base. Over the manufacturing
procedure, viability of the harvested cells has shown to be
robust and above 80% except for validation 2, which showed a
viability of 65%. During the process, a decrease in viability was
observed on day +6 compared with that observed in starting
cells, and this temporary drop on viability after transduction
has been already reported by other groups (44, 47, 48). Some
authors have reported that NKG2D CAR T cells may induce
fratricide, hindering the expansion and the viability of cultured
cells (49, 50). Additionally, a CD4/CD8 ratio bias and enhanced
effector memory differentiation have been described when using
PBMCs as starting cells to express NKG2D CAR. The fold
NKG2D CAR T cell expansion observed in this study, along
with the viability of the final cell products, suggests that no
NKG2D CAR T cell-mediated fratricide is occurring during the
manufacturing protocol. This observation could be related to the
T-cell subset used as starting cells, as CD45RA− compartment
is already enriched in CD4+ T cells with an effector memory
and central memory phenotypes. However, more experiments
need to be performed to explore the susceptibility of different
T-cell subsets to NKG2D CAR T cell-mediated fratricide to
confirm this hypothesis. To further explore if fratricide could
be taking place in our experiments, the expression of NKG2DL
on NKG2D CAR T cells expanded at small scale was analyzed
by FCM. No upregulation of NKG2DL was observed in these
cells (data not shown). Nevertheless, we only analyzed the
expression of NKG2DL at day +8 post-activation, and it has
been described that activated T cells upregulate NKG2DL in
a temporary manner, specially between days 2 and 5 upon
activation (49, 50). Thus, with our data, we cannot totally rule
out an upregulation of NKG2DL and, consequently, a fratricide
phenomenon in other moments of the culture. A more detailed
study of NKG2DL expression kinetics on NKG2D CAR T
cells along the manufacturing procedure would shed light on
this question.
Activated CD45RA− cells were lentivirally transduced with
MOI = 2 because small-scale preclinical data using the same
vector achieved transduction efficiencies higher than 95% (30).
This MOI of 2 is low compared with that of other works where
MOIs of 5–10 are reported (43, 48). We used a fluorochrome-
labeled anti-NKG2D mAb for CAR detection by FCM, as
untransduced CD45RA− cells only have basal expression of the
NKG2D receptor, and then we can consider that the NKG2D
expression observed in manufactured cells comes from the
CAR (30). The expression of NKG2D CAR in transduced
CD45RA− cells was further confirmed by western blot and PCR
analysis. As previously observed in small-scale experiments, the
expression of NKG2D increased during the expansion of cells.
In two out of four batches, NKG2D CAR expression was over
80%, whereas the other two achieved an expression of 55 and
60.6%. These expression values (55–60.6%) are comparable with
those reported in other publications (43, 51) and were enough
to efficiently eliminate Jurkat and primary osteosarcoma cells
(531MII) at a 20:1 effector to target ratio. Owing to technical
issues, some cytotoxicity assays were non-reproducible, and thus,
potency of NKG2D CAR T cells could not be evaluated at
some time points either during manufacturing procedure or at
the end of culture. Nevertheless, those cytotoxicity assays that
were reproducible also fulfilled the specification for potency,
indicating manufactured NKG2D CAR T cells are cytotoxic
against the target cells.
At the end of the activation–transduction–expansion
protocol, different quality tests need to be performed to ensure
safety and purity of manufactured CAR T cells before they
are administered in patients. Sterility tests were negative, and
no mycoplasma was detected. The concentration of bacterial
endotoxins was within the limits set by Eu Ph for intravenous
injectable products in all validations. Genetic stability of
NKG2D CAR T was confirmed by normal CGH, indicating no
chromosomal aberrations are caused by lentiviral transduction.
Three out of four validations showed <5 genome integrated
vector copies, fulfilling the specifications required. However,
in validation #3, up to 12.3 genome integrated vector copies
were detected. These data are striking, as a MOI of 2 was used
in all experiments and does not match the hypothesis that one
viral particle is able to infect one cell. Despite that higher-
than-expected VCN was found in these cells, the percentage
of NKG2D CAR positive cells in this validation was 87%,
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indicating transduction efficiency was not above the usual levels.
Additionally, CGH and expression of myc and tert oncogenes
were normal in this batch, suggesting that even thoughmore than
five copies were integrated, they caused no genetic alterations.
To rule out a potential oncogenic effect of NKG2D CAR T
cells, the expression of myc and tert oncogenes was analyzed.
All validations showed no overexpression of these genes except
for validation #4, which presented overexpression of myc, and
consequently did not fulfill the specifications required. Although
myc overexpression in NK cell products has been previously
demonstrated to be safe and to induce no complications nor
secondary neoplasia in patients (52), it would be important to be
aware and increase monitoring of these cell products to ensure
safety before being administered to patients. The specification
of the percentage of RCL in the supernatants is established at a
maximum of 0.05%. All NKG2D CAR T cell products remained
under that limit, indicating that there is no potential risk of virus
infection after infusion.
In summary, the data here reported demonstrate the feasibility
and reproducibility of a manufacturing protocol to obtain
clinical-grade large-scale NKG2D CAR CD45RA− T cells
in CliniMACS Prodigy system. NKG2D CAR T cells met
the release criteria for expansion, NKG2D CAR expression,
cytotoxicity, and sterility, although grade of expansion and
product characteristics showed variability. Most importantly,
the manufacturing process described here shows flexibility
and admits further improvements for future NKG2D CAR T
cell trials.
DATA AVAILABILITY STATEMENT
All datasets generated for this study are included in the
manuscript/Supplementary Files.
ETHICS STATEMENT
The studies involving human participants were reviewed and
approved by The Ethics Committee from Hospital La Paz. Non-
mobilized apheresis was obtained from healthy donors at the
Bone Marrow Transplant and Cell Therapy Unit (BMTCT) of
Hospital Universitario La Paz (HULP) by using CliniMACS
Plus device (Miltenyi Biotec). All donors gave their written
informed consent in accordance with the Helsinki protocol, and
the study was performed according to the guidelines of the Ethics
Committee from Hospital La Paz. The patients/participants
provided their written informed consent to participate in
this study.
AUTHOR CONTRIBUTIONS
LF, IM, and AP-M: conception and design. LF, AF, IM, DL, AM,
and AR: development of methodology. LF, AE, MV, LC, AF,
AL, MG, IM, RP, and AP-M: acquisition of data (acquired and
managed patients, provided facilities, etc.). LF, AF, IM, AE, JM-L,
and AP-M: analysis and interpretation of data (e.g., statistical
analysis, biostatistics, computational analysis). LF, AF, IM, and
AP-M: writing, review, and/or revision of the manuscript. LF,
AF, IM, and AE: administrative, technical, or material support
(i.e., reporting or organizing data, constructing databases). LF
and AP-M: study supervision.
FUNDING
This study was funded in part by the National Health Service of
Spain, Instituto de Salud Carlos III (ISCIII), FONDOS FEDER
grant (FIS) PI18/01301, by the Unoentrecienmil Foundation and
by CRIS Cancer Foundation to beat Cancer (http://criscancer.
org). LF, AF, IM, and AE are granted by CRIS Cancer Foundation
to beat cancer.
ACKNOWLEDGMENTS
We thank St. Jude Children’s Research Hospital, especially Dr.
Byoung and Dr. Robert Throm, for the vector core, for the
design, and for transfer of lentiviral plasmids. We also thank the
Monoclonal Antibodies, Genomics and Flow Cytometry Units
at the CNIO, and Microbiology Department from HULP for
technical support. We are especially grateful to the family of
531MII, MEZ, whose generosity and capacity to see beyond have
allowed so many scientific achievements.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fimmu.
2019.02361/full#supplementary-material
Supplementary Figure 1 | PCR showing expression of endogenous NKG2D
receptor and NKG2D CAR in transduced cells. NKG2D CAR expression is absent
in CD45RA− cells and PBMC negative controls.
Supplementary Figure 2 | Representative FCM data of
CD4+CD25+CD127low/− (Treg) content in total PBMC from a healthy donor (first
row), starting CD45RA− cells from validation 2 (second row), and NKG2D CAR T
cells from validation 4 at the end of manufacturing process (third row).
Supplementary Video 1 | 3.35 h Time-lapse showing how NKG2D CAR memory
T cells (labeled in orange with CMTMR) recognize, bind, and eliminate Jurkat cells
(labeled in green with CFSE).
REFERENCES
1. Lee YH, Kim CH. Evolution of chimeric antigen receptor (CAR) T cell
therapy: current status and future perspectives. Arch Pharm Res. (2019)
42:607–16. doi: 10.1007/s12272-019-01136-x
2. Maus MV, June CH. Making better chimeric antigen receptors
for adoptive T-cell therapy. Clin Cancer Res. (2016) 22:1875–84.
doi: 10.1158/1078-0432.CCR-15-1433
3. Barrett DM, Singh N, Porter DL, Grupp SA, June CH. Chimeric
antigen receptor therapy for cancer. Annu Rev Med. (2014) 65:333–47.
doi: 10.1146/annurev-med-060512-150254
4. June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR
T cell immunotherapy for human cancer. Science. (2018) 359:1361–5.
doi: 10.1126/science.aar6711
5. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al.
Efficacy and toxicity management of 19-28z CAR T cell therapy in
Frontiers in Immunology | www.frontiersin.org 10 October 2019 | Volume 10 | Article 2361
Fernández et al. Clinical-Grade Production of NKG2D CAR T Cells
B cell acute lymphoblastic leukemia. Sci Transl Med. (2014) 6:224ra25.
doi: 10.1126/scitranslmed.3008226
6. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric
antigen receptor T cells for sustained remissions in leukemia. N Engl J Med.
(2014) 371:1507–17. doi: 10.1056/NEJMoa1407222
7. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RPT, Carpenter RO,
Stetler-Stevenson M, et al. Chemotherapy-refractory diffuse large B-cell
lymphoma and indolent B-cell malignancies can be effectively treated with
autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin
Oncol. (2015) 33:540–9. doi: 10.1200/JCO.2014.56.2025
8. Turtle JC, Hanafi LA, Beger C, Hudecek M, Pender B, Robinson E, et al.
Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+
and CD4+CD19-specific chimeric antigen receptor-modified T cells. Sci
Transl Med. (2016) 8:355ra116.doi: 10.1126/scitranslmed.aaf8621
9. Ruella M, Maus MV. Catch me if you can: leukemia escape after CD19-
directed T cell immunotherapies. Comput Struct Biotechnol J. (2016) 14:357–
62. doi: 10.1016/j.csbj.2016.09.003
10. Sotillo E, Barret DM, Black KL, Bagashev A, Oldridge D, Wu G, et al.
Convergence of acquired mutations and alternative splicing of CD19 enables
resistance to CART-19 immunotherapy. Cancer Discov. (2015) 5:1282–95.
doi: 10.1158/2159-8290.CD-15-1020
11. Hilpert J, Grosse-Hovest L, Grünebach F, Buechele C, Nuebling T, Raum T,
et al. Comprehensive analysis of NKG2D ligand expression and release in
leukemia: implications for NKG2D-mediated NK cell responses. J Immunol.
(2012) 189:1360–71. doi: 10.4049/jimmunol.1200796
12. Fernández L, Valentín J, Zalacain M, Leung W, Patiño-García A, Pérez-
Martínez A. Activated and expanded natural killer cells target osteosarcoma
tumor initiating cells in an NKG2D–NKG2DL dependent manner. Cancer
Lett. (2015) 368:54–63. doi: 10.1016/j.canlet.2015.07.042
13. LehnerM, Götz G, Proff J, Schaft N, Dorrie J, Full F, et al. Redirecting T cells to
Ewing’s sarcoma family of tumors by a chimeric NKG2D receptor expressed
by lentiviral transduction or mRNA transfection. PLoS ONE. (2012) 7:e31210.
doi: 10.1371/journal.pone.0031210
14. Cruz CRY, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku S, et al.
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell
malignancies relapsed after allogeneic stem cell transplant: a phase 1 study.
Blood. (2013) 122:2965–74. doi: 10.1182/blood-2013-06-506741
15. Brudno JN, Somerville RPT, Shi V, Rose JJ, Halverson DC, Fowler DH, et al.
Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce
remissions of B-cell malignancies that progress after allogeneic hematopoietic
stem-cell transplantation without causing graft-versus-host disease. J Clin
Oncol. (2016) 34:1112–21. doi: 10.1200/JCO.2015.64.5929
16. Terakura S, Yamamoto TN, Gardner RA, Turtle CJ, Jensen MC, Ridell
SR. Generation of CD19-chimeric antigen receptor modified CD8+ T cells
derived from virus-specific central memory T cells. Blood. (2012) 119:72–82.
doi: 10.1182/blood-2011-07-366419
17. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, et al. Virus-
specific T cells engineered to coexpress tumor-specific receptors: persistence
and antitumor activity in individuals with neuroblastoma. J Exp Med. (2009)
14:1264–70. doi: 10.1038/nm.1882
18. Chan WK, Suwannasaen D, Throm RE, Li Y, Elridge PW, Houston J,
et al. Chimeric antigen receptor-redirected CD45RA-negative T cells have
potent antileukemia and pathogen memory response without graft-versus-
host activity. Leukemia. (2014) 29:1–9. doi: 10.1038/leu.2014.174
19. Anderson BE, McNiff J, Yan J, Doyle H, Mamula M, Shlomchik MJ, et al.
Memory CD4+ T cells do not induce graft-versus-host disease. J Clin Invest.
(2003) 112:101–8. doi: 10.1172/JCI200317601
20. Foster AE, Marangolo M, Sartor MM, Alexander SI, Hu M, Kenneth FB, et al.
Human CD62L–memory T cells are less responsive to alloantigen stimulation
than CD62L+ naive T cells: potential for adoptive immunotherapy and
allodepletion. Cell. (2008) 104:2403–9. doi: 10.1182/blood-2003-12-4431
21. Golubovskaya V, Wu L. Different subsets of T cells, memory,
effector functions, and CAR-T immunotherapy. Cancers. (2016) 8:36.
doi: 10.3390/cancers8030036
22. Mahnke YD, Brodie TM, Sallusto F, Roederer M, Lugli E. The who’s who of
T-cell differentiation: human memory T-cell subsets. Eur J Immunol. (2013)
43:2797–809. doi: 10.1002/eji.201343751
23. Chen BJ, Deoliveira D, Cui X, Le NT, Son J, Whitesides JF, et al. Inability of
memory T cells to induce graft-versus-host disease is a result of an abortive
alloresponse. Blood. (2007) 109:3115–23. doi: 10.1182/blood-2006-04-
016410
24. ChérelM, Choufi B, Trauet J, Cracco P, Dessaint JP, Yakoub-Agha I, et al. Naïve
subset develops the most important alloreactive response among human
CD4+ T lymphocytes in human leukocyte antigen-identical related setting.
Eur J Haematol. (2014) 92:491–6. doi: 10.1111/ejh.12283
25. Zheng H, Matte-Martone C, Li H, Anderson BE, Venketesan S, Tan
HS, et al. Effector memory CD4+ T cells mediate graft-versus-leukemia
without inducing graft-versus-host disease. Blood. (2008) 111:2476–84.
doi: 10.1182/blood-2007-08-109678
26. Hollyman D, Stefanski J, Przybylowski M, Bartido S, Borquez-Ojeda O, Taylor
C, et al. Manufacturing validation of biologically functional T cells targeted
to CD19 antigen for autologous adoptive cell therapy. J Immunother. (2009)
32:169–80. doi: 10.1097/CJI.0b013e318194a6e8
27. Singh H, Figliola MJ, Dawson MJ, Olivares S, Zhang L, Yang G, et al.
Manufacture of clinical-grade CD19-specific T cells stably expressing
chimeric antigen receptor using Sleeping Beauty system and artificial antigen
presenting cells. PLoS ONE. (2013) 8:1–11. doi: 10.1371/journal.pone.00
64138
28. Gee AP. Manufacturing genetically modified T cells for clinical trials. Cancer
Gene Ther. (2015) 22:67–71. doi: 10.1038/cgt.2014.71
29. Imai C, Mihara K, Andreansky M, Nicholson IC, Pui CH, Geiger TL,
et al. Chimeric receptors with 4-1BB signaling capacity provoke potent
cytotoxicity against acute lymphoblastic leukemia. Leukemia. (2004) 18:676–
84. doi: 10.1038/sj.leu.2403302
30. Fernández L, Metais JY, Escudero A, Vela M, Valentín J, Vallcorba
I, et al. Memory T cells expressing an NKG2D-CAR efficiently
target osteosarcoma cells. Clin Cancer Res. (2017) 23:5824–35.
doi: 10.1158/1078-0432.CCR-17-0075
31. Christodoulou I, Patsali P, Stephanou C, Antoniou M, Kleanthous M, Lederer
CW. Measurement of lentiviral vector titre and copy number by cross-species
duplex quantitative PCR. Gene Ther. (2016) 23:113–8. doi: 10.1038/gt.2015.60
32. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative
C(T) method. Nat Protoc. (2008) 3:1101–8. doi: 10.1038/nprot.2008.73
33. FanM, LiM, Gao L, Geng S,Wang J,Wang Y, et al. Chimeric antigen receptors
for adoptive T cell therapy in acute myeloid leukemia. J Hematol Oncol. (2017)
10:1–14. doi: 10.1186/s13045-017-0519-7
34. Scherer LD, BrennerMK,MamonkinM. Chimeric antigen receptors for T-cell
malignancies. Front Oncol. (2019) 9:126. doi: 10.3389/fonc.2019.00126
35. Knochelmann HM, Smith AS, Dwyer CJ, Wyatt MM,Mehrotra S, Paulos CM.
CAR T cells in solid tumors: blueprints for building effective therapies. Front
Immunol. (2018) 9:1–20. doi: 10.3389/fimmu.2018.01740
36. Martinez M, Moon EK. CAR T cells for solid tumors: new strategies for
finding, infiltrating, and surviving in the tumor microenvironment. Front
Immunol. (2019) 10:1–21. doi: 10.3389/fimmu.2019.00128
37. Spear P, Wu MR, Sentman ML, Sentman CL. NKG2D ligands as therapeutic
targets. Cancer Immunity. (2013) 13:8.
38. Schlegel P, Ditthard K, Lang P, Mezger M, Michaelis S, Handgretinger R,
et al. NKG2D signaling leads to NK cell mediated lysis of childhood AML.
J Immunol Res. (2015) 2015:473175. doi: 10.1155/2015/473175
39. Torelli GF, Peragine N, Raponi S, Pagilara D, De Propis MS, Vitale
A, et al. Recognition of adult and pediatric acute lymphoblastic
leukemia blasts by natural killer cells. Haematologica. (2014) 99:1248–54.
doi: 10.3324/haematol.2013.101931
40. Sallman DA, Brayer J, Sagatys EM, Lonez C, Breman E, Agaugué S, et al.
NKG2D-based chimeric antigen receptor therapy induced remission in a
relapsed/refractory acute myeloid leukemia patient. Haematologica. (2018)
103:424–6. doi: 10.3324/haematol.2017.186742
41. Maschan M, Blagov S, Shelikhova L, Shekhovtsova Z, Balashov, D’Starichkova
J, et al. Low-dose donor memory T-cell infusion after TCR alpha/beta depleted
unrelated and haploidentical transplantation: results of a pilot trial. Bone
Marrow Transplant. (2018) 53:264–73. doi: 10.1038/s41409-017-0035-y
42. Gasior M, Bueno D, De Paz R, Mozo Y, Rosich B, Sisinni L, et al. Safety
and outcome of high-dose donor CD45RO+ memory T-cells infusion after
allogeneic transplantation. Bone Marrow Transplant. (2019) 54.
Frontiers in Immunology | www.frontiersin.org 11 October 2019 | Volume 10 | Article 2361
Fernández et al. Clinical-Grade Production of NKG2D CAR T Cells
43. Zhang W, Jordan KR, Schulte B, Purev E. Characterization of clinical
grade CD19 chimeric antigen receptor T cells produced using automated
CliniMACS Prodigy system. Drug Des Dev Ther. (2018) 2018:3343–56.
doi: 10.2147/DDDT.S175113
44. Mock U, Nickolay L, Philip B, Cheung WKG, Zhang H, Johnston ICD, et al.
Automated manufacturing of chimeric antigen receptor T cells for adoptive
immunotherapy using CliniMACS prodigy. Cytotherapy. (2016) 18:1002–11.
doi: 10.1016/j.jcyt.2016.05.009
45. Geyer MB, Brentjens RJ. Review: current clinical applications of chimeric
antigen receptor (CAR) modified T cells. Cytotherapy. (2016) 18:1393–409.
doi: 10.1016/j.jcyt.2016.07.003
46. Baumeister SH, Murad J, Werner L, Daley H, Trebeden-Negre H,
Gicobi JK, et al. Phase I trial of autologous CAR T cells targeting
NKG2D ligands in patients with AML/MDS and multiple myeloma.
Cancer Immunol Res. (2018) 7:100–12. doi: 10.1158/2326-6066.CIR-
18-0307
47. Tumaini B, Lee DW, Lin T, Castiello L, Stroncek DF, Mackall C, et al.
Simplified process for the production of anti-CD19-CAR-engineered
T cells. Cytotherapy. (2013) 15:1406–15. doi: 10.1016/j.jcyt.2013.
06.003
48. Dominick L, Mockel-Tenbrinck N, Drechsel K, Barth C, Mauer D, Schaser
T, et al. Automated manufacturing of potent CD20-directed chimeric
antigen receptor T cells for clinical use. Hum Gene Ther. (2017) 28:914–25.
doi: 10.1089/hum.2017.111
49. Breman E, Demoulin B, Agaugué S, Mauën S, Michaux A, Springuel L, et al.
Overcoming target driven fratricide for T cell therapy. Front Immunol. (2018)
9:2940. doi: 10.3389/fimmu.2018.02940
50. Song DG, Ye Q, Santoro S, Fang C, Best A, Powell DJ Jr. Chimeric NKG2D
CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced
by histone deacetylase inhibition. Hum Gene Ther. (2013) 24:295–305.
doi: 10.1089/hum.2012.143
51. Zhu F, Shah N, XuH, Schneider D, Orentas R, Dropulic B, et al. Closed-system
manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor
T cells using the CliniMACS Prodigy device at an academic medical center.
Cytotherapy. (2018) 20:394–406. doi: 10.1016/j.jcyt.2017.09.005
52. Leivas A, Perez-Martinez A, Blanchard MJ, Martín-Clavero E, Fernández L,
Lahuerta JJ, et al. Novel treatment strategy with autologous activated and
expanded natural killer cells plus anti-myeloma drugs for multiple myeloma.
Oncoimmunology. (2016) 5:e1250051. doi: 10.1080/2162402X.2016.1250051
Conflict of Interest: DL works for Miltenyi Biotec S.L.
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2019 Fernández, Fernández, Mirones, Escudero, Cardoso, Vela,
Lanzarot, de Paz, Leivas, Gallardo, Marcos, Romero, Martínez-López and Pérez-
Martínez. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in
other forums is permitted, provided the original author(s) and the copyright owner(s)
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Immunology | www.frontiersin.org 12 October 2019 | Volume 10 | Article 2361
